Pre-clinical research from VBI Vaccines has demonstrated an encouraging ability to boost and broaden the immune response against the coronavirus Beta variant.
List view / Grid view
VBI Vaccines presents data supporting the use of its eVLP platform to develop a novel HCV vaccine candidate
4 June 2015 | By Victoria White
VBI Vaccines has delivered a presentation that supports the potential use of its eVLP platform in the development of a novel Hepatitis C vaccine candidate...